BlissBio, founded in December 2017, has developed into a clinical-stage biotech company dedicated to the discovery, development and commercialization of oncology biological therapeutics. BlissBio currently has multiple innovative tumor-targeting ADCs in Phase I and Phase II clinical trials, all of which have broad market prospects for a variety of oncology indications. The core team of BlissBio has a successful track record in the research, development and manufacturing of multiple biotherapeutics in this field, has developed several technology platforms as well as a rich pipeline with the products at different stages, and has the capability to manufacture antibodies and ADCs that meet international GMP standards in its own facility. Through international collaborations, BlissBio works closely with partners to jointly promote the research, development and commercialization of differentiated innovative biotherapeutics with global competitiveness.

HC Biopharma Inc. founded in 2020, is a wholly subsidiary of Chengdu Brilliant Pharmaceuticals Co., Ltd.. HC Biooharma discovers, develops and manufactures innovative biologics and biosimilars. Company's portfolio is comprised of monoclonal and multi-specific antibodies and antibody drug conjugate for oncology and autoimmune diseases, representing a combination of synergistic agents to deliver curative patient outcomes.

The co-founder of LongBio, Dr. Sun, Bill, Nai-chau, is also the co-founder of Tanox, with its IPO in Nasdaq at 2000 and acquiredby Genentech in 2007. He is also the co-inventor of Omalizumab (Xolair®, Global sales is 3.9B USD in 2023), the first anti-IgE antibody approved by FDA.
LongBio's leading pipeline candidate, LP-003, is the next generation of anti-IgE antibody and demonstrates potential best-in-class in the anti-IgE field. Clinical results indicate a longer half-life and potential superiority over competitors, coupled with a favorable safety profile. LP-003 is currently in a Phase III study for allergic rhinitis in China, with additional indications, including CSU, asthma, and food allergy in Phase II stage in China.
Another key pipeline, LP-005, is a potential first-in-class bifunctional complement inhibitor. A Phase II study for PNH is currently underway.

SmartNuclide is a Chinese radiopharmaceutical company dedicated to developing innovative radioligand therapies (RLTs) other than the well-established PSMA and SSTR2. We leverage two cutting-edge platforms: nanobody-based RLTs and pre-targeting radioimmunotherapy (PRIT). These platforms empower us to develop novel radiopharmaceuticals for a wide range of tumor targets, addressing the critical unmet needs in current cancer treatments. Our pipeline features a clinical stage theranostic program targeting Claudin 18.2 in gastric and pancreatic cancers (SNA014), and a diverse portfolio of preclinical candidates (SNA025, SNA029, etc.) targeting various cancers including colorectal, lung and kidney cancer.

Founded in 2020, Immunocan is a pioneering biotechnology company transforming therapeutic R&D through its advanced mega-base gene-editing technology. The cornerstone of its innovation, the ImRobust® gene-edited animal suite, generates antibody repertoires of unparalleled diversity, offering high-potential candidates for the discovery and development of complex biologics such as ADCs and bispecific/multispecific antibodies.
Immunocan has launched a broad range of pilot programs in collaboration with pharmaceutical and biotechnology companies, with the goal of fostering long-term partnerships that drive revolutionary increases in R&D efficiency.
Committed to innovation and collaboration, Immunocan continues to develop universal antibody discovery technologies that empower its global partners to accelerate the development of next-generation therapeutics, shaping the future of medicine for unmet medical needs worldwide.

Established at Chengdu China in 2018, Real&Best (R&B) is committed to original research and cost-efficient production. The aim of company is to make rAAV gene therapy “Faster, Better and More Affordable”. A range of platforms based on bioinformatics and AI technology have been developed, covering all necessary elements for rAAV design including promotor, therapeutic gene and capsid. R&B has also completed the full industry chain layout for original rAAV gene therapy including drug development, production platform, and clinical translation.
Relying on technique platforms, R&B has established a pipeline layout including hematology, metabolism, and aging. Currently, rAAV gene therapies for Hemophilia A, Hemophilia B and Fabry have progressed to Phase 1/2 clinical trials. The Fabry disease pipeline is the 1st chinese gene therapy to enter clinical research, preliminary demonstrating its excellent efficacy and safety. For anti-aging, R&B developed the sarcopenia pipeline, which has entered clinical IIT studies, showing initial effects in muscle building and fat reduction. 

VSPharmTech (VSPT), a clinical stage biotechnology company, has been dedicated to developing innovative therapeutics to achieve paradigm shift for cancer patients since its establishment in 2018. VSPT has secured 5 promising anticancer drug candidates, obtained 3 IND approvals from regulatory authorities in Korea and the U.S., and acquired interim Phase 1 clinical trial data in 6 years. Thanks to remarkable achievements in drug development, VSPT was designated an outstanding R&D SME company 2018-2023 in Korea and invited to JLABS, which is an incubation program by Johnson & Johnson. These milestones were achieved through $13M of investment and $4.7M of government grants in Korea.
The most advanced pipeline is a radiosensitizer, which awakens the potential of radiotherapy through making tumor cells more responsive to radiation therapy, has been approved to proceed P2 clinical trials for HNC and BC. From 2025, VSPT plans to accelerate global drug development by focusing on:
1. Demonstrating the efficacy of the radiosensitizer for rare cancers such as glioblastoma with significant unmet medical needs.
2. Confirming the synergy between the radiosensitizer and rapidly growing radiopharmaceuticals.

Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of June 30, 2024, approximately 150 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and nearly 50 target-nominated RenMice® licensing projects have been established with over 60 global pharmaceutical and biotech companies, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn/.

Qingdao Sino-Cell Biomedicine Co., Ltd.(Sino-Cell), established in 2019, is a clinical stage biopharmaceutical company dedicated to the development of innovative tumor infiltrating lymphocytes (TILs) therapeutics for late stage cancer treatment.
With PowerTexp® high-efficiency TIL production process platform and the TMExpT® tumor microenvironment regulation and expression platform, Sino-Cell has two products in clinical development stage. FAST-TILs, in phase I stage, only need 14 days manufacturing time and no high dose IL-2 transfusion is required, that significantly reduced patient’s waiting time and treatment associated SAE. Nice-TILs, in IIT stage, have both cytotoxic T cell and NK cell function and sustained survival/ proliferation activity in tumor microenvironment. 

Shenzhen MagicRNA Biotech Co., Ltd., founded in 2021, focused on the nucleic acid delivery LNP, and we have successfully constructed the engineered cell-targeted lipid nanoparticle (EnC-LNP) platform. As ionizable amine lipid is the most important component of LNP, we have developed the proprietary lipid structure and hold the ionizable lipid library, with the core lipid (ILB-3132) now commercially available. We constructed specific EnC-LNP for cells from the immune system, central nervous system, and tumor cells. MagicRNA has deeply developed its pipelines based on the proprietary EnC-LNP.
HN2301 (in vivo CAR-T producer), MagicRNA’s leading pipeline, using T cell EnC-LNP encapsulated with CD19 CAR mRNA for the treatment of B cell-involved autoimmune diseases, has completed the Preclinical Candidate (PCC) stage and is under IND-Enabling now. HN2301 successfully reprogrammed the CD19 CAR T cells and induced the B cell depletion and reset in both blood and tissues in non-human primates (NHPs) and has verified the therapeutic effects on systemic lupus erythematosus (SLE) model mice. Other pipelines based on the EnC-LNP are under investigation now.

Beijing Sungen Biomedical Technology Co., Ltd is an innovation-driven, clinical-stage biotechnology company founded in 2019, dedicated to advancing human health through cutting-edge technologies. We are pioneering the development of First-in-Class (FIC) and Best-in-Class (BIC) antibody-based therapeutics, including monoclonal (mAbs), bispecific (BsAbs), and conjugated antibodies (ADCs). Supported by a team of dedicated researchers and management with successful biotechnology entrepreneur experiences, Sungen has developed major research and manufacturing platforms in-house, such as AI-powered drug discovery platform. We leverage our innovative technology platforms to transform targeted therapies, focusing on cardiovascular, cancer, and neurodegenerative diseases. It is our commitment to address critical unmet clinical needs and improve patient outcomes worldwide.
Currently, Sungen has 2 prominent pipelines, i.e. SGC001 and SGT003. SGC001 is well positioned to be the FIC antibody drug for acute myocardial infarction (AMI). With a target validated by multiple renowned institutional labs worldwide, SGC001 illustrates a significant dose-dependent efficacy in animal models. Its current phase I clinical trial is going smoothly, indicating excellent safety and toxicity potential.
SGT003 is a bispecific antibody drug targeting Treg cells for pan-cancer treatment. Having CTLA4 as one of the targets, SGT003 indicates better efficacy and safety in animal models. It has a high potential to be the BIC drug among similar products.

Zhuhai Trinomab Pharmaceutical Co., Ltd. (Trinomab) is an innovative biopharmaceutical company with a global expansion perspective that integrates research and development, production and sales. The core technology of the company is known as the fourth-generation antibody technology HitmAb®, a proprietary technology platform featuring differentiated advantages and high efficiency for the discovery of fully native human mAbs against infectious diseases, autoimmune disorders, malignant tumors and other human diseases.
Harnessing the power of HitmAb®, Trinomab is developing a robust product pipeline of fully native human mAbs as candidates for more than 20 different application targets including both foreign antigens such as toxins and viruses and host molecules such as NGF. A number of our lead products are focused on replacing plasma-derived immunoglobulins currently in used against infectious pathogens such as tetanus toxin, rabies virus and cytomegalovirus while some are focused on promoting more effective or neglected therapeutics for children against diseases such as respiratory syncytial virus (RSV) and Varicella-Zoster virus. TNM002 injection，an innovative monoclonal antibody formulation independently developed by the company, is the world's first recombinant anti-tetanus toxin monoclonal antibody for prophylaxis against tetanus. TNM002 has been granted the “Breakthrough” designation from the China NMPA in March 2022, and “Fast-track designation from USA FDA in August of the same year. New Drug Application (NDA) for TNM002 has been formally accepted by China NMPA in December 2023 and has then been awarded with the priority review process by the administration.
Upholding the mission of “create clinical value”, Trinomab has been focused on the R&D and industrialization of fully native human mAbs with the goal to develop novel therapeutics that are safe, efficient and accessible to meet clinical needs and benefits for patients across the globe.

CytosinLab Therapeutics is an epigenetics-focused biotech company, aiming to translate cutting-edge epigenetic anti-tumor research into clinic. Our founding team has over 20 years of profound expertise in the field of epigenetic research. We have established a robust EpigenPLUS platform and, building on this, developed extensive pipelines for treatments of a broad range of hematologic malignancies and solid tumors. We are committed to bring innovative epigenetic therapies to patients worldwide.

Siranbio was established in May 2022 in Suzhou Industrial Park. We are a biotech company specialized in siRNA drug development . Our core team is consisted of top scientists and pioneers of siRNA drugs, and have been awarded as the Gusu Leading Enterprise in 2002.
We have developed comprehensive and proprietary platform technologies which encompass the whole process of siRNA drug development. Robust pipeline products have been developed for CHB functional cure, weight control and chronic pain management.

TYK Medicines, Inc. was established in November 2017 in Life Science Park Changxing Economic Development Zone with a fully functionalized 30,000 square meters world-class drug discovery R&D center; subsequently, the company set up the administrative headquarters, medical affairs, and business development in Shanghai. In Zhengzhou, the company has its small molecule drug screening platform. In addition to the current scope, the company is building DP plants in Changxing, Zhejiang Province, and Songjiang District, Shanghai. Thus, the company is capable of a whole industry chain of innovative drug discoveries, as well as drug manufacturing, which makes the company the first-tier innovative biotechnology company in China.

Shaperon is a clinical-stage biotech company based in Seoul, Korea, with a U.S. subsidiary, Hudson Therapeutics. The company is developing novel small molecule inflammasome inhibitors with a unique mechanism of action. By modulating GPCR19-P2X7, Shaperon’s approach suppresses a broad spectrum of inflammatory cytokines, including IL-1β, IL-18, IL-6, and TNF-α. This mechanism controls both the priming and activation phases of the inflammasome, in contrast to conventional treatments that only target the activation phase. This novel modality is ideally suited to address complex immune-mediated inflammatory disorders.

Ningbo NewBay Technology Development Co., Ltd. is a clinical stage biotech company, its lead asset, NB003, a c-kit inhibitor for Gastrointestinal Stromal Tumors (GIST), is in Phase 1b stage, the Phase 1a data were selected as oral presentation by the Scientific Committees for both 2023 ESMO and 2024 ASCO. 

Founded in July 2020, GenAssist Ltd. (GenAssist) is a pioneering gene editing drug company. The operation entity of GenAssist is located in Suzhou, China, with two subsidiaries in Shanghai (China) and Boston (US). GenAssist has its own proprietary TAM base editing technology. Also, the Company has successfully established high throughput (~10b) unique AAV screening library and innovative gene editing tool platform. The company is dedicated to developing base editing drugs against life-threatening diseases. The first base editing product against Duchenne Muscular Dystrophy has entered clinical trial in August 2024 and will file IND at the end of 2024. GenAssist has closed three rounds of financing from famous VC funds, including Redhill capital, Sequoia China, Astrazeneca&CICC and Baidu VC.
Cooperation needs: B round financing (30M USD), DMD pipeline licensing out, AAV capsid licensing out.

Shanghai Huaota Biopharmaceutical Co., Ltd. (aka ‘Huaota’) was established in September 2013. Huaota is a subsidiary of Zhejiang Huahai Pharmaceutical Co., Ltd.
Driven by innovation and development, Huaota has built comprehensive and integrated platforms to develop novel biologics. The R&D platform at Huaota supports the identification and development of new monoclonal antibodies, bispecific antibodies, fusion proteins, ADC drugs, etc.
Independent research and development drive innovation. Huaota has a diverse product pipeline covering therapeutic areas such as tumors and autoimmune diseases. At present, there are over twenty projects under development. Many of them have obtained IND approval and multiple clinical trials are undertaken in the United States, New Zealand, and China. In 2019, Huaota was certified as High- and New-Technology Enterprise. By now, Huaota has applied for several domestic and international invention patents.
Huaota Biopharmaceutical is actively seeking domestic and international partners to collaborate and advance these projects that aim to provide high-quality, advanced biological drugs to the global market, meeting the demand for accessible and affordable biopharmaceuticals. The vision is to innovate and change the world through these efforts.

Zhejiang Yangli Pharmaceutical Technology Co., Ltd (Vybio) is a Chinese national high-tech enterprise and a technology-based SME focused on developing FIC innovative drugs with global IP. The company’s product portfolio is concentrated on oncology and chronic disease fields. Development pipeline includes drugs for refractory tumors, breast cancer, and chronic diseases, with platforms for precision therapy small-molecule drugs and SiRNA gene-based drugs. The company has developed eight first-in-class drugs, two of which have entered Phase II clinical trials. 

Mabworks is a clinical-stage biopharmaceutical company in China focused on discovering and developing differentiated antibody drugs. We aim to become a globally integrated company, translating scientific breakthroughs into novel therapies for autoimmune diseases and oncology. Our proprietary technology platforms, including ADCC-enhanced and multispecific antibody platforms, support efficient drug development. Our pipeline includes MIL62, a 3rd-generation anti-CD20 antibody for primary membranous nephropathy, and innovative T-cell engagers like MBS303/MSC303 and MBS314 for immune-mediated diseases and multiple myeloma. Strategic collaborations with leading pharma companies validate our capabilities.

Kyinno Bio is an innovative biotech company specializing in multi-specific antibody discovery. It has developed a differentiated pipeline centered on bi-specific and tri-specific antibodies, with a focus on First-in-Class (FIC) and Best-in-Class (BIC) therapies in the fields of oncology and autoimmune diseases. In addition to its cutting-edge pipeline, Kyinno Bio also offers groundbreaking antibody discovery services through its proprietary platform. For more information, visit http://www.kyinno.com/

With a team that has successfully developed six protein degraders now in clinical trials, Innovo Therapeutics has built a proprietary molecular glue discovery platform. This platform integrates a rationally designed molecular glue library with a disease-relevant, biology-driven screening system.
Our library, meticulously crafted from over 100 novel chemical scaffolds distinct from lenalidomide, pomalidomide, and their analogs, is on track to include 47,000 compounds upon completion. Leveraging decades of experience in optimizing molecular glue degraders, our biology-driven screening system enables rapid progression from high-quality hits to lead optimization and development candidates (DCs).
We operate with exceptional efficiency in both execution and capital utilization. In just 2.5 years and with $22 million in funding, we have identified 24 neo-substrates through our platform, 22 of which are novel and unreported by others. This combination of a powerful platform, extensive expertise, and operational excellence empowers us to build a deep, highly differentiated pipeline that stands out in the protein degradation field.
Our novel molecular glue INNO-740 is poised to enter Phase 1 clinical trials for hematologic malignancies in 2025. Additionally, three other molecular glues targeting previously “undruggable” proteins demonstrate strong activity against solid tumors—an area where most protein degradation companies face significant challenges. These innovative degraders are central to our strategy as we build a DAC (degrader-antibody conjugate) portfolio through strategic collaborations.

ImmVira is a clinical-stage biotechnology company focusing on developing HSV-1 based oncolytic virotherapy, with established end-to-end capabilities from drug discovery to CMC, inherently reducing modality related development risks.
Leveraging HSV-1 as well-validated oncolytic agent, ImmVira’s core product MVR-T3011 adopted evolved backbone design with enhanced efficacy and modernized IO payload PD-1 and IL12, targeting a wide range of solid tumors via intratumoral (IT), intravenous (IV) and intravesical (IP) injection. MVR-T3011 is undergoing 7 Phase I/II clinical trials in the US and China, with head and neck (IT) and bladder cancer (IP) as leading indications. 

Founded in 2010, Wuhan YZY Biopharma Co., Ltd. (02496.HK) is a global biotechnology leader in treating oncology and autoimmune diseases. Specializing in innovative bispecific antibodies (BsAb), the company leverages its proprietary platforms, YBODY®, Check-BODY, and Nano-YBODY™, to develop a diverse pipeline of preclinical and clinical products. Key therapies include M701 (EpCAM×CD3 BsAb) for malignant ascites, Y101 (PD-L1×TGFβ BsAb) for solid tumors, and Y332 (VEGF×TGFβ BsAb) also for solid tumors.
Notably, M701 (EpCAM×CD3), a CD3-recruiting BsAb developed based on the YBODY® platform, has entered Phase 3 clinical trials for malignant ascites and demonstrated favorable safety and efficacy in Phase 2 trials. Additionally, Phase 1b/2 trials for M701 in malignant pleural effusion are ongoing.
With a mission to safeguard global health, Wuhan YZY Biopharma continues to innovate and collaborate to meet urgent healthcare needs worldwide.